Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis

Open access
Wang, Feng, He, Ming-Ming, Yao, Yi-Chen, Zhao, Xia, Wang, Zhi-Qiang, Jin, Ying, Luo, Hui-Yan, Li, Ji-Bin, Wang, Feng-Hua, Qiu, Miao-Zhen, Lv, Zhi-Da, Wang, De-Shen, Li, Yu-Hong, Zhang, Dong-Sheng, Xu, Rui-Hua·2021·Cell Reports Medicine

Abstract

This is a phase Ib/II study of regorafenib plus toripalimab for colorectal cancer. The objective response rate (ORR) is 15.2% and the disease control rate is 36.4% in evaluable patients with recommended phase II dose (80 mg regorafenib plus toripalimab). The median progression-free survival (PFS) and the median overall survival are 2.1 months and 15.5 months, respectively. Patients with liver metastases have lower ORR than those without (8.7% versus 30.0%). All patients (3/3) with lung-only metastasis respond, whereas no patients (0/4) with liver-only metastasis respond. 94.9% and 38.5% of patients have grade 1 and grade 3 treatment-related adverse events, respectively. Gut microbiome analysis of the baseline fecal samples shows significantly increased relative abundance and positive detection rate of Fusobacterium in non-responders than responders. Patients with high-abundance Fusobacterium have shorter PFS than those with low abundance (median PFS = 2.0 versus 5.2 months; p = 0.002).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xcrm.2021.100383

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 167

Metadata

Authors
Wang, F., He, M.-M., Yao, Y.-C., Zhao, X., Wang, Z.-Q., Jin, Y., Luo, H.-Y., Li, J.-B., Wang, F.-H., Qiu, M.-Z., Lv, Z.-D., Wang, D.-S., Li, Y.-H., Zhang, D.-S., & Xu, R.-H.
Venue
Cell Reports Medicine
Publisher
Elsevier BV
Published
2021-09
Volume
2
Issue
9
Pages
100383
ISSN
2666-3791 (ISSN-L)
OpenAlex
W3197648290
Cited by
167
References
13
FWCI
8.40
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. https://app.cochat.ai/papers/10.1016/j.xcrm.2021.100383
The paper
Wang, F., He, M.-M., Yao, Y.-C., Zhao, X., Wang, Z.-Q., Jin, Y., Luo, H.-Y., Li, J.-B., Wang, F.-H., Qiu, M.-Z., Lv, Z.-D., Wang, D.-S., Li, Y.-H., Zhang, D.-S., & Xu, R.-H. (2021). Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2021.100383

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.